← All trials
NCT02685605
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2016
- Primary completion
- Jun 1, 2020
- Completion date
- Feb 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 314
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of MannheimLead sponsor
- University of California, Los AngelesCollaborator
- University of HeidelbergOverall official - principal investigator
- University of MannheimReponsible party - principal investigator
- Carl Zeiss Meditec, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.